Treatment of steroid refractory acute and chronic graft-versus-host disease with daclizumab

被引：95

作者：

Willenbacher, W ^{[1
]}

Basara, N ^{[1
]}

Blau, IW ^{[1
]}

Fauser, AA ^{[1
]}

Kiehl, MG ^{[1
]}

机构：

[1] BMT Programme, Clin Haematol Oncol, D-55743 Idaroberstein, Germany

来源：

BRITISH JOURNAL OF HAEMATOLOGY | 2001年 / 112卷 / 03期

关键词：

graft-versus-host disease; BMT; daclizumab; interleukin 2 receptor antibody; GVHD;

D O I：

10.1046/j.1365-2141.2001.02582.x

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Competitive inhibition of interleukin 2-dependent lymphocytes by daclizumab demonstrates some beneficial effects in the treatment of graft-versus-host disease (GVHD), Sixteen patients with steroid refractory GVHD received daclizumab (1 mg/kg BW) on d 1, 2 (-5), 7, 14 and 21. Twelve patients suffered from grade LU-nr acute GVHD and four patients from extensive chronic GVHD. Responses were observed in nine patients (six acute, three chronic GVHD). Fourteen out of 16 patients acquired infections during daclizumab treatment and three deaths were infection related. Daclizumab demonstrates limited activity and is associated with an increased incidence of infectious complications.

引用

页码：820 / 823

页数：4

共 12 条

[1]

ANASETTI C, 1994, BLOOD, V84, P1320

[2] IMPAIRMENT OF LEUKEMIA-FREE SURVIVAL BY ADDITION OF INTERLEUKIN-2-RECEPTOR ANTIBODY TO STANDARD GRAFT-VERSUS-HOST PROPHYLAXIS [J].

BLAISE, D ;

OLIVE, D ;

MICHALLET, M ;

MARIT, G ;

LEBLOND, V ;

MARANINCHI, D .

LANCET, 1995, 345 (8958) :1144-1146

[3] Cytomegalovirus infections after treatment with daclizumab, an anti IL-2 receptor antibody, for prevention of renal allograft rejection [J].

Hengster, P ;

Pescovitz, MD ;

Hyatt, D ;

Margreiter, R .

TRANSPLANTATION, 1999, 68 (02) :310-313

[4] A prospective randomized trial comparing interleukin-8 receptor antibody versus antithymocyte globulin as part of a quadruple immunosuppressive induction therapy following orthotopic liver transplantation [J].

Langrehr, JM ;

Nussler, NC ;

Neumann, U ;

Guckelberger, O ;

Lohmann, R ;

Radtke, A ;

Jonas, S ;

Klupp, J ;

Steinmuller, T ;

Lobeck, H ;

Meuer, S ;

Schlag, H ;

Lemmens, HP ;

Knoop, M ;

Keck, H ;

Bechstein, WO ;

Neuhaus, P .

TRANSPLANTATION, 1997, 63 (12) :1772-1781

[5] A randomized prospective study comparing low-dose OKT3 to low-dose ATG for the treatment of acute steroid-resistant rejection episodes in kidney transplant recipients [J].

Mariat, C ;

Alamartine, E ;

Diab, N ;

de Filippis, JP ;

Laurent, B ;

Berthoux, F .

TRANSPLANT INTERNATIONAL, 1998, 11 (03) :231-236

[6] A low incidence of grade II to IV acute GVHD, but high mortality from, infection using HLA-A, -B, and -DR-identical unrelated donors and immunosuppression with ATG, cyclosporine, and methotrexate [J].

Mattsson, J ;

Ringden, O ;

Aschan, J ;

Barkholt, L ;

Dalianis, T ;

Hagglund, H ;

Ljungman, P ;

Lonnqvist, B ;

Tollemar, J ;

Winiarski, J ;

Remberger, M .

TRANSPLANTATION PROCEEDINGS, 1997, 29 (1-2) :735-736

[7] THE OUTCOME OF MATCHED UNRELATED DONOR BONE-MARROW TRANSPLANTATION IN PATIENTS WITH HEMATOLOGIC MALIGNANCIES USING MOLECULAR TYPING FOR DONOR SELECTION AND GRAFT-VERSUS-HOST DISEASE PROPHYLAXIS REGIMEN OF CYCLOSPORINE, METHOTREXATE, AND PREDNISONE [J].

NADEMANEE, A ;

SCHMIDT, GM ;

PARKER, P ;

DAGIS, AC ;

STEIN, A ;

SNYDER, DS ;

ODONNELL, M ;

SMITH, EP ;

STEPAN, DE ;

MOLINA, A ;

WONG, KK ;

MARGOLIN, K ;

SOMLO, G ;

LITTRELL, B ;

WOO, D ;

SNIECINSKI, I ;

NILAND, JC ;

FORMAN, SJ .

BLOOD, 1995, 86 (03) :1228-1234

[8] Daclizumab, a humanized anti-interleukin-2 receptor alpha chain antibody, for treatment of acute graft-versus-host disease [J].

Przepiorka, D ;

Kernan, NA ;

Ippoliti, C ;

Papadopoulos, EB ;

Giralt, S ;

Khouri, I ;

Lu, JG ;

Gajewski, J ;

Durett, A ;

Cleary, K ;

Champlin, R ;

Andersson, BS ;

Light, S .

BLOOD, 2000, 95 (01) :83-89

[9]

STORB R, 1990, BLOOD, V76, P1037

[10]

Van Lint MT, 1998, BLOOD, V92, P2288

← 1 2 →